Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02778750 · ClinicalTrials.gov registry record
Evaluation Of The Pan-microbiome and Host Immune Response in CF
A clinical trial, sponsored by NYU Langone Health.
- Completed
- Registry status
- 12
- Enrollment target
NCT02778750: Completed study, sponsored by NYU Langone Health.
NCT02778750 is a clinical trial that has completed, run by NYU Langone Health. The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02778750 has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- 12 participants
- Enrollment target
Study Summary
Investigators will examine temporal and regional dynamic changes in the microbiome of Cystic Fibrosis patients to explore microbiome features that are associated with an inflammatory phenotype. Investigators hypothesize that temporal and spatial differences in lung microbiome are associated with host inflammatory responses. While chronic and polymicrobial airway colonization are commonly recognized in cystic fibrosis (CF), it is unclear what factors of the microbial environment lead to infection with pathogenic microorganism. This is a multi center, longitudinal cohort of adult Cystic Fibrosis subjects recruit4ed from NYU and Columbia to understand how changes in the airway microbiome may affect the host inflammatory responses in Cystic Fibrosis (CF). There will be three approaches to understanding inflammatory responses; 1) a longitudinal assessment of temporal changes in the microbiome over a 6-month period of clinical stability; 2) comparison of the regional differences in airway microbiome between lung segments with more versus less disease; 3) evaluation of functional aspects of the lung microbiome.
Interventions
- PROCEDURE Two-Bronchoscope Technique
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2015-06-05 |
| Est. Completion | 2020-03-12 |
What the finished NCT02778750 record still lists
NCT02778750 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 12 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Two-Bronchoscope Technique is the first listed.
NCT02778750 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02778750 about?
NCT02778750 is a clinical study titled "Evaluation Of The Pan-microbiome and Host Immune Response in CF". Investigators will examine temporal and regional dynamic changes in the microbiome of Cystic Fibrosis patients to explore microbiome features that are associated with an inflammatory phenotype. Investigators hypothesize that temporal and spatial differences in lung microbiome are associated with hos...
What is the current status of trial NCT02778750?
This trial is currently completed. The enrollment target is 12 participants. The study started on 2015-06-05. Estimated completion is 2020-03-12.
What interventions are being tested in trial NCT02778750?
The interventions under investigation include: Two-Bronchoscope Technique (PROCEDURE).
Who is sponsoring clinical trial NCT02778750?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI